6
Clinical Trials associated with JSKN016评估JSKN016联合治疗在不可手术切除局部晚期或转移性HER2阴性乳腺癌参与者中的疗效和安全性的临床研究
[Translation] A clinical study to evaluate the efficacy and safety of JSKN016 combination therapy in participants with unresectable locally advanced or metastatic HER2-negative breast cancer
主要目的:评价JSKN016联合治疗在晚期HER2阴性乳腺癌参与者的抗肿瘤活性。
次要研究目的:评价JSKN016联合治疗治疗晚期HER2阴性乳腺癌参与者的其他抗肿瘤活性、安全性和耐受性;评价JSKN016的药代动力学(PK)特征、免疫原性。
探索性目的:探索肿瘤组织标本(存档或新鲜活检标本)生物标志物和临床疗效之间的相关性。
[Translation] Primary objective: To evaluate the anti-tumor activity of JSKN016 combination therapy in participants with advanced HER2-negative breast cancer.
Secondary study objectives: To evaluate other anti-tumor activities, safety and tolerability of JSKN016 combination therapy in participants with advanced HER2-negative breast cancer; to evaluate the pharmacokinetic (PK) characteristics and immunogenicity of JSKN016.
Exploratory objective: To explore the correlation between biomarkers and clinical efficacy in tumor tissue specimens (archive or fresh biopsy specimens).
/ Not yet recruitingPhase 1/2 The Multicenter, Open-label, Single-arm, Multi-cohort Phase Ib/II Clinical Study to Evaluate the Efficacy and Safety of JSKN016 in Combination Therapy in Chinese Participants With Inoperable Locally Advanced or Metastatic HER2-negative Breast Cancer
This study aims to evaluate the safety and effectiveness of JSKN016 in combination with different treatments for patients with HER2-negative breast cancer that cannot be removed by surgery or has spread to other parts of the body. The study includes four groups of patients based on treatment history and tumor characteristics. Each group will receive JSKN016 with chemotherapy or immunotherapy. The goal is to find out how well the treatment works and how safe it is.
/ Not yet recruitingPhase 1 Evaluation of JSKN016 Combination Therapy in Subjects with Advanced Non-Small Cell Lung Cancer: a Phase Ib Study
This is a Phase Ib clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016 in combination therapy. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.
100 Clinical Results associated with JSKN016
100 Translational Medicine associated with JSKN016
100 Patents (Medical) associated with JSKN016
100 Deals associated with JSKN016